PRIAS: Active surveillance for men with low risk prostate cancer
Prof Monique J. Roobol - Erasmus University Medical Center, Rotterdam, The Nethe...
PRIAS: Active surveillance for men with low risk prostate cancer ( Prof Monique J. Roobol - Erasmus University Medical Center, Rotterdam, The Netherlands )
24 Feb 2020
EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic...
Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA
EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )
19 Feb 2020
KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC
Dr Julie Graff - Oregon Health & Science University, Portland, USA
KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC ( Dr Julie Graff - Oregon Health & Science University, Portland, USA )
19 Feb 2020
BCG dosing for bladder cancer: Standard frequency schedule correct
Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany
BCG dosing for bladder cancer: Standard frequency schedule correct ( Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany )
19 Feb 2020
RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma
Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA
RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma ( Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA )
19 Feb 2020
CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC
Dr Anis Hamid - Dana-Farber Cancer Institute, Boston, USA
CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC ( Dr Anis Hamid - Dana-Farber Cancer Institute, Boston, USA )
19 Feb 2020
Integrative molecular characterisation of S/R RCC to reveal determinants of poor...
Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA
Integrative molecular characterisation of S/R RCC to reveal determinants of poor prognosis and response to ICIs ( Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA )
18 Feb 2020
Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or ...
Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA
Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or targeted therapy ( Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA )
18 Feb 2020
NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally advan...
Dr Syed Hussain - University of Sheffield, Sheffield, United Kingdom
NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer ( Dr Syed Hussain - University of Sheffield, Sheffield, United Kingdom )
18 Feb 2020
OSPREY: PSMA-targeted PET/CT imaging in prostate cancer patients
Dr Frédéric Pouliot - Centre Hospitalier Universitaire (CHU) de Quebec
OSPREY: PSMA-targeted PET/CT imaging in prostate cancer patients ( Dr Frédéric Pouliot - Centre Hospitalier Universitaire (CHU) de Quebec )
18 Feb 2020
ASCO GU 2020: Bladder: Genomic profiling, real-world treatment challenges and no...
Dr Petros Grivas, Dr Shilpa Gupta, Dr Alison Birtle and Dr Joseph Jacob
ASCO GU 2020: Bladder: Genomic profiling, real-world treatment challenges and novel agents ( Dr Petros Grivas, Dr Shilpa Gupta, Dr Alison Birtle and Dr Joseph Jacob )
14 Feb 2020
Sitravatinib and nivolumab combo for advanced clear cell renal cell cancer
Dr Pavlos Msaouel - The University of Texas MD Anderson Cancer Center, Houston, ...
Sitravatinib and nivolumab combo for advanced clear cell renal cell cancer ( Dr Pavlos Msaouel - The University of Texas MD Anderson Cancer Center, Houston, USA )
14 Feb 2020